News Sentiment

CRSP sentiment intelligence

Crispr Therapeutics AG news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 53.35 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-11.2% over one week, +7.1% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Negative

CRISPR Therapeutics Stock 6-Day Losing Spree: Stock Falls 18%

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -11.2% Price reacting lower
Trend fit Trend inactive 7.1% over four weeks
Fair value 0.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 37
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
TradingView 11
The Motley Fool 4
Ad-hoc-news.de 4
MarketBeat 3
Trefis 2
Moomoo 2
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 18
Analyst action 5
Guidance 2
Balance sheet 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
TradingView Direct company coverage

Enterprise value to EBITDA forward of CRISPR Therapeutics AG – NASDAQ:CRSP

This article provides the enterprise value to EBITDA forward for CRISPR Therapeutics AG (NASDAQ: CRSP). It indicates that the market was closed at the time of publication with no trades, and offers various financial and community data points related to the company.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 06:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of CRISPR Therapeutics AG – DUS:1CG

This article displays the "Enterprise value to EBIT forward" for CRISPR Therapeutics AG, listed under the stock symbol DUS:1CG on the Dusseldorf Stock Exchange. It indicates no trades occurred and provides a market closed status. The content is presented as a financial data point

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 02:10
Source
TradingView
Kavout | AI Direct company coverage

Is CRISPR Therapeutics (CRSP) Finally Ready for Prime Time After Casgevy's Initial Success

CRISPR Therapeutics (CRSP) is transitioning into a commercial-stage biotech with the initial success of its gene-editing therapy, Casgevy, which exceeded Q4 2025 sales expectations and shows accelerating patient adoption. Beyond Casgevy, CRSP boasts a robust pipeline including th

Tone
Positive 74/100
Event
Market update
Published
26 Jun 2026 13:09
Source
Kavout | AI
TradingView Direct company coverage

CRISPR Therapeutics AG Actuals & Estimates (NASDAQ:CRSP)

This article provides an overview of CRISPR Therapeutics AG (NASDAQ: CRSP) stock performance, financial data, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, and upcoming earnings reports, along with other financial metr

Tone
Positive 61/100
Event
Earnings
Published
25 Jun 2026 20:09
Source
TradingView
TradingView Direct company coverage

CRSP Forecast — Price Target — Prediction for 2027

The article provides a forecast and price target for CRISPR Therapeutics AG (CRSP) stock, based on analyst opinions. It includes current stock performance metrics, historical price data, upcoming earnings report dates, and various financial figures such as market capitalization,

Tone
Positive 61/100
Event
Analyst action
Published
25 Jun 2026 14:40
Source
TradingView
Quartr Direct company coverage

CRISPR Therapeutics (CRSP) TD Cowen 46th Annual Health Care Conference Summary

CRISPR Therapeutics presented its strategic shift towards a disease-focused model at the TD Cowen 46th Annual Health Care Conference, emphasizing cardiovascular and autoimmune franchises with expected data from six programs beyond Casgevy by mid-2027. The company detailed strong

Tone
Positive 76/100
Event
Market update
Published
21 Jun 2026 18:11
Source
Quartr
TradingKey Direct company coverage

CRISPR Therapeutics AG (CRSP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for CRISPR Therapeutics AG (CRSP), covering business segments, regional revenue, and profit contribution. However, it explicitly states that the relevant data for these categories has not yet been disclosed by t

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 17:39
Source
TradingKey
Simply Wall Street Direct company coverage

Is CRISPR Therapeutics’ (CRSP) ESOP Shelf Registration Quietly Redefining Its Long‑Term Risk‑Reward Profile?

CRISPR Therapeutics (CRSP) recently filed a US$969.16 million ESOP-related shelf registration and amended its articles of association, prompting investors to re-evaluate the company's long-term risk-reward profile. While these moves reinforce equity-based compensation and balance

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 15:43
Source
Simply Wall Street
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA)

Analysts have issued neutral ratings for enGene Holdings (ENGN) and Intellia Therapeutics (NTLA), indicating an evenly balanced outlook. Wells Fargo assigned a Hold rating to enGene Holdings with a $2.00 price target, while Bank of America Securities maintained a Hold rating on I

Tone
Neutral 50/100
Event
Analyst action
Published
17 Jun 2026 10:10
Source
The Globe and Mail